Colorectal Cancer Diagnostics Market To Witness Massive Growth By 2033
The global colorectal cancer diagnostics market size was estimated at USD 9.53 billion in 2025 and is projected to reach USD 14.39 billion by 2033, growing at a CAGR of 5.34% from 2026 to 2033.
The global colorectal cancer diagnostics market size was estimated at USD 9.53 billion in 2025 and is projected to reach USD 14.39 billion by 2033, growing at a CAGR of 5.34% from 2026 to 2033. This steady growth reflects the increasing importance of early detection and timely diagnosis in improving patient outcomes. The industry is primarily driven by the rising incidence of colorectal cancer across both developed and developing regions, along with the growing awareness among patients and healthcare providers regarding the benefits of early screening. In addition, there is a significant rise in demand for diagnostic solutions that are not only accurate but also efficient and accessible. The growing adoption of non-invasive screening methods, such as stool-based and blood-based tests, is further accelerating market expansion. Moreover, continuous advancements in molecular and genomic diagnostic technologies are enhancing detection capabilities, enabling more precise identification of cancer at early stages and supporting personalized treatment approaches.
The rising prevalence of colorectal cancer, particularly among younger adults who were previously considered at lower risk, is further increasing the need for effective and widespread screening and diagnostic approaches. Lifestyle changes, dietary patterns, and genetic predispositions are contributing to this shift, making early detection even more critical. In addition, the growing financial burden associated with colorectal cancer treatment, including surgery, chemotherapy, and long-term care, is encouraging healthcare systems to prioritize cost-effective and efficient diagnostic solutions that can reduce overall treatment expenses through early intervention. Technological advancements in genomics and molecular diagnostics are playing a crucial role in improving the accuracy, sensitivity, and personalization of colorectal cancer detection.
The global burden of colorectal cancer continues to rise, making it one of the most commonly diagnosed cancers worldwide and a major public health concern. According to estimates from the International Agency for Research on Cancer and findings from the GLOBOCAN study published in Gut, approximately 1.9 million new colorectal cancer cases and over 930,000 related deaths were reported globally in 2020. These figures highlight the significant impact of the disease on global mortality and healthcare systems. Future projections suggest an even more alarming trend, with the global burden expected to increase to around 3.2 million new cases and 1.6 million deaths annually by 2040. This anticipated growth underscores the urgent need for improved diagnostic infrastructure, expanded screening programs, and greater investment in research and innovation to combat the disease effectively and reduce its long-term impact.
Key Market Trends & Insights
- North America colorectal cancer diagnostics market dominated the market and accounted for the largest revenue share of 38.82% in 2025. This dominance can be attributed to the presence of well-established healthcare infrastructure, high awareness levels regarding cancer screening, and the widespread availability of advanced diagnostic technologies. Favorable reimbursement policies and strong government support for cancer screening initiatives have also contributed to the region’s leading position in the market.
- The U.S. led the North America market and held the largest revenue share in 2025. The country’s leadership is driven by its advanced healthcare system, strong focus on research and development, and early adoption of innovative diagnostic technologies. In addition, the presence of major diagnostic companies and increasing participation in routine screening programs further strengthen the market in the U.S.
- Based on product, the diagnostic kits and assays segment dominated the global market and accounted for the largest revenue share of 41.96% in 2025. This dominance is largely due to the widespread use of these kits in routine screening and diagnostic procedures, along with their ability to provide reliable and rapid results. Continuous innovation in assay development is also enhancing their effectiveness and expanding their applications.
- Based on test type, the stool based tests segment held the largest revenue share of 60.30% in 2025. These tests are widely preferred due to their non-invasive nature, ease of use, and suitability for at-home screening. Their growing acceptance among patients and healthcare providers is significantly contributing to their market dominance.
- Based on cancer type, the adenocarcinoma segment held the largest revenue share of 92.80% in 2025. This is primarily because adenocarcinoma is the most common type of colorectal cancer, accounting for the majority of diagnosed cases. As a result, most diagnostic solutions are designed to detect this specific cancer type.
Looking for more specific insights? Customize this report to suite your business needs
Key Colorectal Cancer Diagnostics Companies Insights
The competitive landscape of the colorectal cancer diagnostics market is characterized by the presence of several global diagnostic companies that focus on molecular diagnostics, screening technologies, and advanced imaging solutions. These companies are continuously striving to strengthen their market position through product innovation, obtaining regulatory approvals, forming strategic collaborations, and expanding their diagnostic portfolios. The market remains relatively consolidated, with the top ten industry leaders, including companies such as Exact Sciences and Roche, accounting for nearly 50% of the global market revenue. This concentration highlights the strong influence of key players in shaping market trends and technological advancements.
Competitive dynamics are increasingly being shaped by the industry’s shift toward liquid biopsy technologies and non-invasive molecular screening solutions. Leading companies are investing heavily in research and development to introduce innovative products that offer higher accuracy, convenience, and early detection capabilities. To maintain and enhance their long-term leadership, these companies are actively pursuing strategic mergers and acquisitions, as well as focusing on technological innovation and precision diagnostics initiatives. Their efforts are primarily directed toward integrating high-sensitivity genomic profiling and advanced molecular diagnostics into routine clinical practice, thereby addressing the growing demand for early cancer detection and personalized treatment strategies.
Recent Developments
In March 2026, Guardant Health, Inc. announced that its blood-based colorectal cancer screening test, Shield, became accessible through the national test ordering and collection network of Quest Diagnostics. Through this collaboration, physicians can order the Shield test via Quest’s electronic health record systems, and patients can complete screening through Quest’s nationwide network of patient service centers and phlebotomists, significantly expanding access to non-invasive blood-based colorectal cancer screening and improving patient convenience.
In July 2025, Exact Sciences Corporation expanded its colorectal cancer screening partnership with Humana Inc. to improve access to the Cologuard Plus test. Under the agreement, the non-invasive stool-based screening test will be available as an in-network service for eligible Humana Medicare Advantage members across the U.S. starting August 2025. This initiative is expected to enhance patient participation in screening programs by providing a convenient and accessible at-home testing option.
In May 2024, Geneoscopy Inc. received U.S. FDA approval for ColoSense, a non-invasive multi-target stool RNA test designed for colorectal cancer screening in adults aged 45 years and older at average risk. The test detects colorectal cancer and advanced adenomas using RNA biomarkers from stool samples, offering a convenient and accurate screening alternative. This approval marks the introduction of the first FDA-approved stool RNA-based colorectal cancer screening test, significantly expanding the availability of molecular diagnostic solutions for early cancer detection.
Explore Grand View Horizon to see global and regional level statistics related to the Colorectal Cancer Diagnostics Market
Grand View Research offers
- Focused market intelligence reports on specific geographies or high-growth segments.
- Extended forecast timelines for long-term planning.
- Competitor Benchmarking and Supply Chain Analysis
- Inclusion of regulatory and policy assessments.
- Inclusion of custom data models, KPIs, or applications unique to your business
- Specific high-impact Data Decks and Tables to support effective decision making
- And much more…
Looking for a report customized to your requirements? Explore our Custom Research Offering
Contact:
Grand View Research, Inc.
Office No. 705, A Wing, 7th Floor,
Amar Business Zone,
Veerbhadra Nagar, Baner,
Pune, MH, 411045 India
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Explore Our New Service : https://www.grandviewresearch.com/services/brainshare